Περίληψη:
OBJECTIVE. The purposes of this article are to review the common
biologic features of cancer and coronary artery disease assessed with
PET tracers, focusing on those already used in the clinic and those with
translational potential, and to discuss the current value and expected
contribution of PET in diagnosis, risk stratification, and treatment
monitoring.
CONCLUSION. PET using a wide variety of radiotracers enhances
understanding of pathophysiologic changes shared by cancer and coronary
artery disease, helps establish an accurate diagnosis, and aids in
prognostic assessment and management decisions. It is likely that with
the evolution of therapeutic strategies for blocking the development and
progression of both diseases and with the introduction of novel,
specific ligands in clinical practice, PET will play an ever stronger
role in diagnosis, risk stratification, and monitoring of therapy.
Συγγραφείς:
Paschali, Anna N.
Nekolla, Stephen G.
Evangelou, Konstantinos
and Cook, Gary J.
Anagnostopoulos, Constantinos D.